Midazolam Accordpharma (Midazolam)

Midazolam binds to the benzodiazepine site on the GABA‑A receptor complex, enhancing the inhibitory action of the neurotransmitter GABA. This increases chloride ion influx, hyperpolarising neurons and leading to reduced neuronal excitability, which manifests as sedation, anxiolysis, muscle relaxation and seizure suppression.

The specific dose of Midazolam Accordpharma is determined by the prescribing clinician based on the patient’s age, weight, clinical condition and route of administration. Dosing guidelines are provided in the product’s prescribing information and must be individualized for each patient.

Midazolam is classified as a pregnancy‑category drug with limited safety data; it should only be used if the potential benefit justifies the potential risk to the fetus. It is excreted in breast milk, so caution is advised for nursing mothers, and alternative therapies should be considered when possible.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and import documentation.

Compared with other benzodiazepines, Midazolam has a rapid onset and relatively short duration of action, making it suitable for procedural sedation and emergency seizure control. Its pharmacokinetic profile differs from longer‑acting agents like diazepam, offering quicker recovery times after short procedures.

Midazolam Accordpharma should be stored at 2‑8 °C in a refrigerator, protected from light. The vial must not be frozen or shaken. If temperature control cannot be maintained, the product should be discarded to ensure potency and safety.

Midazolam is administered by intramuscular or intravenous injection. The route, rate of infusion and total dose are determined by the clinician based on the intended use—whether for sedation, anesthesia induction or seizure termination.

The most serious risks include severe respiratory depression, profound hypotension, anaphylactic reactions, paradoxical agitation and, in rare cases, cardiac arrhythmias. Continuous monitoring of respiratory and cardiovascular status is essential, especially when combined with other depressant agents.

Midazolam is contraindicated in patients with known hypersensitivity to benzodiazepines, severe respiratory insufficiency, acute narrow‑angle glaucoma, and those who are pregnant or breastfeeding unless the benefit outweighs the risk. Caution is also required for individuals with significant hepatic impairment.